Arcus Biosciences (RCUS) Misses Q1 EPS by 12c

Arcus Biosciences (NYSE: RCUS) reported Q1 EPS of ($1.14), $0.12 worse than the analyst estimate of ($1.02). Revenue for the quarter came in at $28 million versus the consensus estimate of $38.61 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• U.S. presses Meta to agree to A.I. reviews as security concerns rise - NYT
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat